DRUG EBITDA Growth
-283.96%TTM
Period ending:
DRUG TTM EBITDA YoY %%
339.30%-2133.43%
2021-09-302026-06-30
Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.
DRUG ebitda growth history
Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 17 observations from Sep 30, 2021 to Jun 30, 2026.
| Period ending | EBITDA Growth |
|---|---|
| -283.9591% | |
| -716.1614% | |
| -1,894.1305% | |
| -345.3637% | |
| -153.6735% | |
| 34.9754% | |
| 85.0891% | |
| 62.6199% | |
| 60.1582% | |
| 29.193% | |
| -26.1037% | |
| -147.0293% | |
| -378.7643% | |
| 100% | |
| 100% | |
| 100% | |
| -29.9937% |
Compare ebitda growth
All DRUG financial metrics · DRUG stock overview · How to interpret financial metrics
